This study is not yet accepting patients

A Randomized Controlled Trial to Compare the Effectiveness of a Patient-reported Outcomes-driven Supportive Care Navigation Among Hispanic/Latinx Cancer Patients

a study on Cancer, General Neoplasms

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine
Dates
study started
study ends around
Principal Investigator
by Alexandre Chan, PharmD, PhD, MPH (uci)
Headshot of Alexandre Chan
Alexandre Chan

Description

Summary

This is a randomized controlled, type 1 hybrid effectiveness-implementation trial to evaluate the effectiveness of a patient-reported outcomes (PRO)-driven culturally grounded supportive care navigation in reducing healthcare disparities among Hispanic/Latinx patients receiving anticancer therapies. The objectives of this study are: (1) to compare the effectiveness of an ePRO-driven culturally grounded supportive care navigation versus usual care (control) in Hispanic/Latinx patients undergoing anticancer treatment; and (2) to elicit perspectives from Hispanic/Latinx patients, healthcare providers, and community partners on how an ePRO-driven culturally grounded supportive care navigation can address health disparities.

Official Title

A Randomized Controlled, Type 1 Hybrid Effectiveness-implementation Trial Study to Compare the Effectiveness of a Patient-Reported Outcomes (PRO)-Driven Culturally Grounded Supportive Care Navigation in Reducing Healthcare Disparities Among Hispanic/Latinx Patients Receiving Anticancer Therapies

Keywords

Cancer, patient navigation, patient-reported outcomes, supportive care in cancer, cancer survivorship, Neoplasms, Patient Reported Outcome Measures, Patient-Reported Outcomes (PRO)-driven supportive care navigation

Eligibility

You can join if…

Open to people ages 18 years and up

  • At least 18 years old
  • Hispanic/LatinX origin
  • Newly diagnosed cancer patients
  • Receiving anticancer treatment (may include combinations of intravenous or oral chemotherapy, targeted therapies, and/or immunotherapies)

You CAN'T join if...

  • Being physically and/or mentally incapable of providing written consent

Location

  • Chao Family Comprehensive Cancer Center
    Irvine California 92617 United States

Lead Scientist at University of California Health

  • Alexandre Chan, PharmD, PhD, MPH (uci)
    Clinical Professor, Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences. Authored (or co-authored) 360 research publications

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Irvine
ID
NCT07787806
Study Type
Interventional
Participants
Expecting 72 study participants
Last Updated